New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.

Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination therapies for platinum-resistant ovarian cancer. The approvals include a ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s MRK Keytruda (pembrolizumab) and ...

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total ...

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug.  | As Merck ...

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...

Merck to present data across multiple genitourinary cancers from several approved and investigational medicines at 2026 ASCO GU cancers symposium: Rahway, New Jersey Saturday, Feb ...

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and ...